Industry
E-nitiate Biopharmaceuticals (Hangzhou) Co., Ltd.
Total Trials
5
Recruiting
0
Active
0
Completed
1
Success Rate
100.0%+13% vs avg
Key Highlights
Risk & Performance
Pipeline Risk Assessment
Pipeline Risk Assessment
Based on historical performance
Moderate Risk
Score: 35/100
Failure Rate
0.0%
0 terminated/withdrawn out of 5 trials
Success Rate
100.0%
+13.5% vs industry average
Late-Stage Pipeline
20%
1 trials in Phase 3/4
Results Transparency
0%
0 of 1 completed trials have results
Key Signals
Enrollment Performance
Analytics
Phase 1
3(60.0%)
Phase 3
1(20.0%)
Phase 2
1(20.0%)
5Total
Phase 1(3)
Phase 3(1)
Phase 2(1)
Activity Timeline
Global Presence
Loading network data...
Clinical Trials (5)
Showing 5 of 5 trials
NCT07180511Phase 3Enrolling By Invitation
A Phase III Clinical Study of QY201 Tablet in Subjects With Moderate to Severe Atopic Dermatitis.
Role: lead
NCT06170840Phase 2Unknown
A Study of QY101 Ointment in Subjects With Plaque Psoriasis
Role: lead
NCT05429177Phase 1Completed
A First-in-Human Study of QY101 Ointment in Adult Subjects
Role: lead
NCT05843422Phase 1Unknown
A First-in-Human Study of QY211 Gel in Adult Subjects
Role: lead
NCT05525715Phase 1Unknown
A Study of QY201 Tablet in Subjects With Moderate to Severe Atopic Dermatitis
Role: lead
All 5 trials loaded